ARCT
Arcturus Therapeutics Holdings Inc.
Biotechnology · Healthcare · United States
12.15
close · 2026-10-29
value
44
cheaper than peers44
quality
18
stronger fundamentals18
ranked against
Biotechnology (commercial)
value
quality
161 peerswide variation
Value inputs
| measure | company | vs peers |
| cash flow yield, 3 years ago | 10.4% | 95 |
| earnings yield, 3 years ago | 4.3% | 95 |
| EV to EBITDA | 0.11× | 93 |
| price to sales | 3.16× | 86 |
| price to book | 2.01× | 72 |
| earnings yield, 2 years ago | -12.2% | 32 |
| cash flow yield, 2 years ago | -9.0% | 23 |
| cash flow yield, latest year | -31.8% | 14 |
| cash flow yield, 1 year ago | -25.8% | 14 |
| earnings yield, 1 year ago | -36.5% | 5 |
| earnings yield, latest year | -29.2% | 5 |
11 of 12 measures available
Quality inputs
| measure | company | vs peers |
| return on equity | -37.0% | 63 |
| debt to equity | 12.5% | 58 |
| operating margin | -1403.7% | 18 |
| revenue growth | -93.0% | 3 |
4 of 4 measures available
Facts
| market cap | $345M |
| free cash flow | $11.3M |
| employees | 106 |
| first trade | 2013-05-22 |
| next earnings | 2026-11-05 |
| fundamentals updated | 2026-08-06 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | -2.40 | -3.00 | -1.00 | 0.35 |
| free cash flow | -$74.5M | -$60.4M | -$21.0M | $24.3M |
| net income | -$65.8M | -$80.9M | -$29.7M | $9.3M |
| revenue | $67.2M | $138.4M | $157.7M | $205.8M |
| unusual items | $382,000 | -$471,000 | $33.7M | -$598,000 |